These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10974635)

  • 1. Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells.
    Takahashi M; Kigawa J; Minagawa Y; Itamochi H; Shimada M; Kamazawa S; Sato S; Akeshima R; Terakawa N
    Eur J Cancer; 2000 Sep; 36(14):1863-8. PubMed ID: 10974635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of the combination effect of wild-type TP53 gene transfection and cisplatin treatment for ovarian cancer xenografts.
    Shimada M; Kigawa J; Kanamori Y; Itamochi H; Takahashi M; Kamazawa S; Sato S; Terakawa N
    Eur J Cancer; 2000 Sep; 36(14):1869-75. PubMed ID: 10974636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination effect of adenovirus-mediated pro-apoptotic bax gene transfer with cisplatin or paclitaxel treatment in ovarian cancer cell lines.
    Tsuruta Y; Mandai M; Konishi I; Kuroda H; Kusakari T; Yura Y; Hamid AA; Tamura I; Kariya M; Fujii S
    Eur J Cancer; 2001 Mar; 37(4):531-41. PubMed ID: 11267864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase activity and p53-dependent apoptosis in ovarian cancer cells.
    Akeshima R; Kigawa J; Takahashi M; Oishi T; Kanamori Y; Itamochi H; Shimada M; Kamazawa S; Sato S; Terakawa N
    Br J Cancer; 2001 Jun; 84(11):1551-5. PubMed ID: 11384107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 gene status and chemosensitivity in ovarian cancer.
    Kigawa J; Sato S; Shimada M; Takahashi M; Itamochi H; Kanamori Y; Terakawa N
    Hum Cell; 2001 Sep; 14(3):165-71. PubMed ID: 11774736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells.
    Sato S; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Iba T; Naniwa J; Uegaki K; Terakawa N
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):247-52. PubMed ID: 14610615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
    Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
    Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular efflux pump and interaction between cisplatin and paclitaxel in ovarian cancer cells.
    Kamazawa S; Kigawa J; Minagawa Y; Itamochi H; Shimada M; Takahashi M; Sato S; Akeshima R; Terakawa N
    Oncology; 2000 Nov; 59(4):329-35. PubMed ID: 11096346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53.
    Jones NA; Turner J; McIlwrath AJ; Brown R; Dive C
    Mol Pharmacol; 1998 May; 53(5):819-26. PubMed ID: 9584207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone.
    Sugimura M; Sagae S; Ishioka S; Nishioka Y; Tsukada K; Kudo R
    Oncology; 2004; 66(1):53-61. PubMed ID: 15031599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.
    Ramirez PT; Gershenson DM; Tortolero-Luna G; Ramondetta LM; Fightmaster D; Wharton JT; Wolf JK
    Gynecol Oncol; 2001 Dec; 83(3):543-8. PubMed ID: 11733969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
    Song K; Li Z; Seth P; Cowan KH; Sinha BK
    Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer.
    Kamazawa S; Kigawa J; Kanamori Y; Itamochi H; Sato S; Iba T; Terakawa N
    Gynecol Oncol; 2002 Aug; 86(2):171-6. PubMed ID: 12144824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel.
    Debernardis D; Siré EG; De Feudis P; Vikhanskaya F; Valenti M; Russo P; Parodi S; D'Incalci M; Broggini M
    Cancer Res; 1997 Mar; 57(5):870-4. PubMed ID: 9041188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of BclXL in a human ovarian carcinoma cell line: paradoxic effects on chemosensitivity in vitro versus in vivo.
    Rogers PM; Beale PJ; Al-Moundhri M; Boxall F; Patterson L; Valenti M; Raynaud F; Hobbs S; Johnston S; Kelland LR
    Int J Cancer; 2002 Feb; 97(6):858-63. PubMed ID: 11857368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells.
    Kanamori Y; Kigawa J; Minagawa Y; Irie T; Oishi T; Shimada M; Takahashi M; Nakamura T; Sato K; Terakawa N
    Eur J Cancer; 1998 Oct; 34(11):1802-6. PubMed ID: 9893672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation.
    Mansouri A; Zhang Q; Ridgway LD; Tian L; Claret FX
    Oncol Res; 2003; 13(6-10):399-404. PubMed ID: 12725530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity.
    Giannakakou P; Robey R; Fojo T; Blagosklonny MV
    Oncogene; 2001 Jun; 20(29):3806-13. PubMed ID: 11439344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells.
    Kigawa J; Sato S; Shimada M; Kanamori Y; Itamochi H; Terakawa N
    Gynecol Oncol; 2002 Feb; 84(2):210-5. PubMed ID: 11812076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.